TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System
Representing the next generation in bifurcation stenting, the Antares(TM) system has potential use in a quarter of the 2.2 million angioplasty procedures performed annually worldwide. Antares(TM) stents are not yet approved in the United States and are limited by Federal law to investigational use.
"We are very pleased to achieve this significant milestone that allows commercialization of our Antares(TM) stent system in Europe," said Eitan Konstantino, PhD, President and Chief Executive Officer of TMI. "We believe that the Antares(TM) stent system represents a breakthrough in the treatment of patients suffering from coronary artery disease at or near bifurcations.
"I like the Antares(TM) system concept. The system is designed to fit all classes of bifurcation lesions, irrespective of the size and angulation of the side-branch," said Professor Carlo Di Mario from Royal Brompton Hospital in London. "The operator does not need to commit to a pre-determined side branch treatment and has the flexibility to do what is right for the patient."
Lesions at or near side branches in the coronary tree pose multiple challenges to interventional cardiologists. Combining a low profile stent with a proprietary delivery system, the Antares(TM) system provides a unique set of solutions to the challenges of bifurcation stenting. It can be delivered and deployed in a single step while maintaining access to the side branch and scaffolding the ostium, or the origin of the side branch. As a result, the cardiologist has greater flexibility of treatment options, with the freedom to deploy a second stent in the side branch when additional support is necessary.
"The Antares(TM) stent system is an elegant solution to treat bifurcation lesions that is focused on the main vessel," observed Alexandre Abizaid, MD, PhD, Chief of Coronary Interventions at the Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil. Dr. Abizaid continued, "It increases operators' confidence by providing continuous side branch access throughout the procedure."
About TriReme Medical Inc.
TriReme Medical Inc. (TMI) is a privately held medical device company backed by Three Arch Partners and Adams Street Partners. TMI is based in California and dedicated to the development and manufacturing of novel stent technology for the treatment of atherosclerotic disease at or near bifurcations.
Source: TriReme Medical Inc.